alprazolam has been researched along with Cushing Syndrome in 3 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study is to verify whether acute pre-treatment with alprazolam (ALP), a benzodiazepine that inhibits HPA secretion in normal subjects, could better characterize patients with subclinical Cushing's syndrome (SCS) than the 1-mg dexamethasone test (DST)." | 7.79 | Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing's syndrome. ( Arvat, E; Berardelli, R; D'Angelo, V; Fussotto, B; Ghigo, E; Giordano, R; Karamouzis, I; Manzo, M; Mengozzi, G; Picu, A; Zichi, C, 2013) |
| "The purpose of this study is to verify whether acute pre-treatment with alprazolam (ALP), a benzodiazepine that inhibits HPA secretion in normal subjects, could better characterize patients with subclinical Cushing's syndrome (SCS) than the 1-mg dexamethasone test (DST)." | 3.79 | Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing's syndrome. ( Arvat, E; Berardelli, R; D'Angelo, V; Fussotto, B; Ghigo, E; Giordano, R; Karamouzis, I; Manzo, M; Mengozzi, G; Picu, A; Zichi, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giordano, R | 2 |
| Berardelli, R | 1 |
| Karamouzis, I | 1 |
| D'Angelo, V | 1 |
| Picu, A | 1 |
| Zichi, C | 1 |
| Fussotto, B | 1 |
| Manzo, M | 1 |
| Mengozzi, G | 1 |
| Ghigo, E | 2 |
| Arvat, E | 2 |
| Krapf, R | 1 |
| Grottoli, S | 1 |
| Gauna, C | 1 |
| Maccagno, B | 1 |
| Ramunni, J | 1 |
| Maccario, M | 1 |
| Deghenghi, R | 1 |
1 trial available for alprazolam and Cushing Syndrome
| Article | Year |
|---|---|
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Topics: Adrenocorticotropic Hormone; Adult; Alprazolam; Anti-Anxiety Agents; Corticotropin-Releasing Hormone | 1999 |
2 other studies available for alprazolam and Cushing Syndrome
| Article | Year |
|---|---|
Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing's syndrome.
Topics: Alprazolam; Cushing Syndrome; Dexamethasone; Female; GABA-A Receptor Agonists; Humans; Hydrocortison | 2013 |
Development of Cushing's syndrome after use of a herbal remedy.
Topics: Alprazolam; Betamethasone; Cushing Syndrome; Drugs, Chinese Herbal; Glucocorticoids; Humans; Plant E | 2002 |